Yourgene

Yourgene's Taipei subsidiary will promote the Take2 Prophecy test in Taiwan and will establish a clinical network for the collection of patient blood samples.

For the half year ended Sept. 30, Yourgene booked £8.2 million ($10.7 million) in revenues, up from £7.8 million during the same period last year.

News items for the in vitro diagnostic industry for the week of Oct. 19, 2020.

Yourgene will provide its Elucigene DPYD tests to screen approximately 200 patients each month for the next year.

News items for the in vitro diagnostics industry for the week of Oct. 5, 2020

News items for the in vitro diagnostics industry for the week of Sept. 28, 2020.

The deal includes UK-based Yourgene's test for detecting cancer patients who may have an adverse reaction to 5-fluorouracil, as well as reproductive health tests.

News items for the in vitro diagnostics industry for the week of August 10, 2020.

Coastal Genomics owns the Ranger gel electrophoresis technology to collect specific DNA target sizes, with applications in noninvasive prenatal testing and oncology.

The Clarigene SARS-CoV-2 IVD kit uses two viral RNA targets, nucleocapsid gene N and envelope gene E, which are specific to COVID-19, the firm said.